Aprea Therapeutics Stock Forecast
NASDAQ: APREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:38 PM ET
APRE analyst consensus
Consensus (3 analysts)
none
Avg. price target
$3.73+539.90%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Aprea Therapeutics (2026-10-09), 3 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $3.73, with a high estimate of $5.00 and a low estimate of $1.20. The average target implies upside of 539.9% from the current price of $0.5829.
The spread between the highest and lowest targets is 316.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for APRE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 33% |
| Buy | 2 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.20 | +105.87% |
| Average target | $3.73 | +539.90% |
| High target | $5.00 | +757.78% |